Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction

NCT: NCT02876042 · COMPLETED

NCT IDNCT02876042
StatusCOMPLETED
Start Date2017-03-23
Completion2025-11-03
SponsorCVRx, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

The purpose of this registry (NCT02876042) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO system in the commercial setting in subjects recently implanted under the CE-Marked indication for resistant hypertension that also have evidence of heart failure with preserved ejection fraction (HFpEF).

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑